Sex Education Stagnating In U.S. Schools

By David Beasley at Reuters.com

Public schools in the United States are making “little progress” in expanding instruction in how to prevent pregnancy and sexually transmitted diseases such as HIV, a new federal study concluded.

Between 2008 and 2010, the percentage of public schools teaching key topics on prevention did not increase in the 45 states surveyed, the Centers for Disease Control and Prevention said.

In middle schools, 11 states saw declines during the two-year period and no state saw an increase, the CDC said. The level of instruction was stable in high schools.

“Little progress is how we’re describing it,” Laura Kann, one of the authors of the study, told Reuters.

The study did not explain why this type of instruction appears to be stagnating, Kann said. “The decision about what gets taught is a local decision,” she said. “We asked schools what they are doing. We don’t ask why.”

Public school instruction can be effective in lowering rates of teen pregnancy and sexually transmitted diseases such as HIV, said Kann.

“We have evidence that teaching these topics can contribute to reduction in risk for HIV, STDs and pregnancy,” she said.

The CDC survey found that the percentage of schools teaching all 11 of its suggested prevention topics in grades 6, 7, or 8 ranged from 12.6 percent in Arizona to 66.3 percent in New York.

Schools teaching eight of the suggested topics in grades 9-12 ranged from 45.3 percent in Alaska to 96.4 percent in New Jersey.

Suggested topics for both middle school and high school include the benefits of sexual abstinence.

The push for higher test scores in recent years could mean that schools are less likely to expand health education, Monica Rodriguez, president and chief executive of the nonprofit group, the Sexuality Information and Education Council of the United States, told Reuters.

Also, the question of how best to teach students about preventing pregnancy and sexually transmitted diseases remains a divisive issue in many areas, Rodriguez said.

“For many teachers, it’s often about fear, fear of controversy,” she said

Barriers and Solutions: Linking People To Care, And Keeping Them Engaged In It.

HIV Care on the Front Line

by Benjamin Ryan at POZ.com

Despite the advent of lifesaving treatment that also controls the spread of HIV/AIDS, 30 years into the AIDS epidemic, almost 1 million Americans living with the virus remain untreated for HIV. For years, the prevailing wisdom has been that the barriers to linking people to care—and keeping them engaged in it—were too great to solve the problem. But a handful of warriors on the front line show that we can indeed keep more people alive while slowing the spread of AIDS.

Thirty years into the AIDS Pandemic, despite the fact that we have much effective treatment for HIV, we haven’t tipped the balance in our favor in the fight against AIDS—especially in the United States. The new infection rate for a disease that is preventable has remained flat here for nearly a decade. And yet, around the world, HIV incidence rates are declining: proof positive that we have the tools to turn the tide against HIV. So why can’t we do it in America? The short answer is: We can, we’re just not applying the best strategies where they’re needed most. That may soon change if a few frontline warriors have their way.In December 2011, a new report issued by the Centers for Disease Control and Prevention (CDC) painted a stark reality. It showed that one in five HIV-positive Americans don’t know they’re living with the virus. Worse, of the estimated 960,000 Americans who do know they are living with HIV, only about half are in regular medical care. And, stunningly, of the 1.2 million Americans estimated to be living with HIV, a mere 28 percent are on medication that keeps their HIV infection from leading to AIDS and also helps stop the spread of the virus. One study found that monogamous heterosexuals with HIV who take their medication as prescribed and have an undetectable viral load for at least six months can see a 96 percent reduction in the risk of transmitting HIV to their negative partners.

Today we are armed with powerful, simplified HIV drug regimens, so how is it that we are still failing to treat the HIV community on such a grand scale? For years, people have argued that the barriers to care were simply insurmountable. Indeed, a study conducted in 1999 by the Johns Hopkins HIV Clinic in Baltimore showed how a host of life stressors challenged that city’s urban HIV population so severely that the clinic was unable to keep its clients in long-term HIV treatment. At that time, only 37 percent of Hopkins’s HIV patients in the study had suppressed viral loads. For people of color, the rate was a dismal 25 percent. Sadly, the data made many HIV doctors across the country reluctant to prescribe HIV meds to at-risk patients.

But the times they are a-changin’. In August 2011, the HIV team at Hopkins released a new study showing a stunning turnaround in the health of the HIV-positive people they treat. Between 2003 and 2009, Hopkins retained an impressive 94 percent of its clients—a population that has grown older and included more women and heterosexuals—in care. By 2010, 84 percent of the HIV clients at Hopkins had a fully suppressed viral load. The results proved that new approaches could lead to a new era of access to care for people living with HIV, and that HIV providers can help even the most high-risk populations be effectively treated with HIV therapy. (A third of Hopkins’s clients self-reported injection drug use.)

“Antiretroviral Therapy: Now ‘It Just Works’” is the title of an editorial commentary on the Hopkins results written by Paul Sax, MD, clinical director of the HIV program at Brigham and Women’s Hospital in Boston, and published in the September 2011 issue of Clinical Infectious Diseases. It has become a motto for many who previously abandoned hope for the health of their patients.

In the shadow of the CDC’s scary stats from last year, the recent success at Johns Hopkins has led the CDC to issue a rallying call to solve the problem. The federal agency asked public health officials and HIV providers to follow a key element of the Obama administration’s National HIV/AIDS Strategy: namely, to improve patient engagement at every step along the continuum of care, starting with a positive HIV test, through immediate linkage to care and commencement of treatment, and including retention in care for the long term.

The Hopkins results suggested that the key to connecting people to—and keeping them in—care is overcoming the constellation of risk factors that affect wide swaths of the HIV population: homelessness, substance abuse, stigma, poverty, lack of transportation, lack of medical coverage, fear or mistrust of the medical system and impatience with red tape and bureaucratic hassles.

Any one of these can cause people to miss their appointments. A missed appointment is the time when HIV providers and social service agencies need to be on high alert for ways to re-engage patients and to work with them to address and resolve those barriers to care. Indeed, doing so involves a lot of hard work and a commitment to getting results.

Richard Moore, MD, director of the Johns Hopkins Hospital HIV Clinic and coauthor of the new study, breaks it down. His team has succeeded against all odds, he says, by providing a kind of home away from home for people living with HIV. Primary care and all kinds of specialty care are provided under one roof. Using an electronic records system in place for two decades to keep tabs on every patient, medical providers work with a team of social workers and other support staff to make sure people don’t fall through the cracks.

“If a patient misses a couple of appointments in a row, you wonder if there’s something interfering in their life that’s making it hard for them to come in, or maybe they’re fatiguing in regard to care,” Moore says. “Knowing that patient may be having problems and giving them a call, routing them to see a case worker or something of that sort is one way we use our system to try to troubleshoot before an issue gets out of hand.”

The Hopkins group is also always looking for ways to integrate new HIV treatment guidelines into its practice. And thanks to the electronic records system, it’s easier for providers to monitor the effectiveness of new medical approaches and protocols and to measure their success.

Kaiser Permanente is another group that has been highly effective at engaging and keeping people in its HIV program; 95 percent of the national network’s HIV-positive clients have suppressed viral loads. Eager to export Kaiser’s model and share the lessons his team learned from years of experience treating people with HIV, Michael Horberg, MD, the program’s director, challenges other HIV providers to improve patient retention and care. Kaiser can enter aggregate patient information into a database, allowing Kaiser to compare treatment achievements among HIV providers across the country. Horberg’s division offers free mentorship to other health care providers nationwide and presents tools and information on its website, kp.org/hivchallenge.

Meanwhile, the National Quality Center, NQC, an initiative of the New York State Department of Health, has also created a program to export proven care models across the country. Currently, it is working with 400 U.S. HIV providers who serve over 400,000 positive people. Encouraging retention in care is a central goal. NationalQualityCenter.org, the group’s website, presents a clearinghouse of information for HIV care providers. The center also offers opportunities for mentorship from academic researchers and other coaches.

Is sharing best practices enough, or do we need structural shifts in health care to get more of these hundreds of thousands of untreated people with HIV into care—and test those who still don’t know they have HIV?

“Mentoring is a great idea,” says Moore, adding that his Johns Hopkins clinic has also hosted visiting HIV providers from around the world for mentorship sessions. “Inasmuch as a practice that may not have the resources can get tips about maintaining retention or keeping up to date with guidelines, that’s fine. But our rather fragmented health care system doesn’t support that very well at the moment. I’m hoping that some of the changes taking place over the next two years will help support that. I don’t think that there are easy solutions here.”

While Hopkins produced the evidence that the right techniques work to connect people to and keep them in care, and Kaiser Permanente and the NQC will do their best to help roll out best practices, the best role models remain those organizations (some large and well-funded, some small and struggling) that learn new techniques every day as they fight HIV in some of the most challenging arenas. Often, what distinguishes their work is the ability to provide the critical personal touches that make the difference when it comes to getting people with HIV committed to long-term care.

POZ asked representatives of three such groups what works—and why.

Click HERE to read what Sabrina Heard of DC’s “The Women’s Collective”, Dr. Bookhardt-Murray of NY’s “Harlem United”, and Mark Douglas of Georgia’s “My Brothaz” have to say about how to get and keep patients in care. 

UCLA CFAR, AIDS Institute, and UCLA CTSI Accepting Letters of Intent for Seed Grant Proposals

The UCLA Center for AIDS Research (CFAR), AIDS Institute and the UCLA Clinical and Translational Science Institute (CTSI) are accepting Letters of Intent for seed grant proposals to encourage multidisciplinary collaborations in innovative, unmet, and/or emerging areas of research. 

Multidisciplinary Collaboration -HIV/AIDS -Basic Science
Applicants are invited to submit proposals focused in AIDS-related areas that include studies on viral gene expression, host cell interactions, immune responses to HIV, mechanisms of AIDS lymphoma growth, pathogenesis of opportunistic infectious agents, mechanisms of AIDS dementia, drug and vaccine development, gene therapy, studies of viral RNA expression and DNA levels in infected patients and mechanisms of HIV 1 drug and immune resistance, microbicides and mucosal immunology, and stem cell related approaches to HIV/AIDS.

Multidisciplinary Collaboration -HIV/AIDS -Clinical
Applicants are invited to submit proposals focused in AIDS areas that include studies on the clinical manifestations of HIV and its associated diseases, their treatment or complications of therapy, clinical observational studies, retrospective or prospective clinical outcomes research, treatment interventions or epidemiology studies with a clear clinical focus. Basic laboratory studies, preclinical investigations and social or group observational or interventional studies are not supported by this RFA.

The goal of these grants is to encourage collaborations between multiple disciplines and CTSI institutions and to develop preliminary data for future submissions of program projects or equivalent.

Funding level: A single, multi-disciplinary project for each RFA will be funded, up to a maximum of $200,000 direct costs.

Project period: 2 years (earliest start date, July 1st 2012).

Deadlines
Letters of Intent: 4pm May 1, 2012

Full Proposal:  4pm June 4, 2012

Please see attached RFAs for more information.

[Download not found]

[Download not found]

Facebook: The next tool in fighting STDs

Herpes? Dislike. Cutting-edge sex researchers are using social networks to prevent STDs from going viral

BY TRACY CLARK-FLORY

As seen on Salon.com

Imagine being able to download a Facebook app that would alert you to your sexually transmitted infection risk based on your friend’s status updates. This may sound far-fetched, and it still is, but as some researchers shift their focus to risk among friend groups, as opposed to just sexual partners, social networks are rapidly becoming a tool to prevent the spread of STIs.

Peter Leone, a professor of medicine at the University of North Carolina’s Center for Infectious Diseases, is one of those experts. Earlier this month, he spoke at an international health conference and underscored the importance of exploring such possibilities. Real-world social networks — in other words, a person’s circle of friends and sexual partners — have already proved to be strong predictors of STI risk, he says. It follows that sites like Facebook, which convene all of those real-world connections in one virtual setting, have huge potential in this arena.

Leone found that when sexual partners of patients newly diagnosed with HIV came in for testing, 20 percent turned up HIV-positive. It might seem counter-intuitive to extend the targeted test circle to those a newly diagnosed patient is merely friends with, but people in the same social circle often sleep with the same people, and might engage in similar risk-related behavior. Instead of looking at people within a particular at-risk demographic, this approach allows them to target known clusters of infection.

Makes you think of the people on your “Close Friends” list a bit differently, doesn’t it?

Leone gives the example of a syphilis outbreak in North Carolina: “When we looked at the networks we could connect many of the cases to sexual encounters, and when we asked who they hung out with, who they knew, we could connect 80 percent of the cases.”

Leone’s team asks patients newly diagnosed with HIV for a list of sexual partners and friends who they think might benefit from testing. Then, with the patients’ permission — permission that is more likely in North Carolina because partner notification, in one form or another, is required by law — they will contact people, sometimes using Facebook, with the alarming news that someone they know has been diagnosed with HIV, and that they might be at risk and should be tested.

There is a major shift here away from the traditional approach of either targeting at-risk demographics — like African-American men who have sex with men — or sexual partners of those infected. “People think that you have to be directly connected to someone, and I think of it as a population-level effect,” he says. “It would be no different from someone who goes to a picnic and gets food poisoning. We’re concerned about everyone that was at that picnic.”

To further streamline the process, researchers have also been experimenting with mailing kits to patients who can then collect their own swabs for tests like gonorrhea or chlamydia — or even HIV. “I think that’s the future,” says Leone.

There are other potential approaches that are more reliant on Facebook — like the hypothetical STI app — but those come with serious privacy concerns. James Fowler, a professor of medical genetics at the University of California, San Diego, and author of “Connected: The Surprising Power of Our Social Networks and How They Shape Our Lives,” has already helped develop an app that utilizes status updates on a social networking platform to predict one’s risk of catching the flu. Certain keywords in your newsfeed might signal an increased risk of catching the virus, and the app could notify you accordingly. Instead of saying, “You have a chance of getting the flu in September,” he says, the app tells you, “You have a chance of getting the flu today.”

A similar application for STI risk is imaginable, although certainly more complicated. The spread of the flu is more straightforward and based on basic contact, as opposed to carnal entanglement. “The difference is there’s much less stigma to finding out which one of your friends has the flu,” he says. It would be a dramatic understatement to say that people are much less likely to post status updates about their herpes flare-up than about their nasty stomach bug.

There are plenty of other prevention approaches that are both easier to implement and less likely to raise major privacy red flags. Common wisdom has it that the power of social networks is in making things go viral, but that isn’t enough when it comes to safe sex messaging. “Spreading information is easy. Changing behavior is hard,” Fowler says. Instead of simply delivering a simple message like “wear condoms,” the aim is to set examples within social networks. “There is good evidence that [in terms of sexual behavior] we’re influenced by seeing what our friends are doing,” he says. “It takes real, deep, close social contact for people to change their behavior.” For example, if someone’s friends start posting status updates about getting tested themselves, it might destigmatize and normalize it. That’s the aim of MTV’s and The Kaiser Foundation’s GYT campaign, which has called on young people to get themselves tested and check in on Foursquare while at their local clinic.

Sean Young, a researcher at UCLA’s Division of Infectious Diseases, tells me that social networking sites are most useful as portals for information and conversation about risk and testing. He’s done research where at-risk individuals are recruited and trained to participate in Facebook groups where they then talk about testing and pass along important resources, all in an attempt to “change social norms that HIV testing is both healthy and admired behavior.”

The research in this area is still young, and there are more dazzling hypotheticals than concrete solutions, but many researchers have a basic intuition that social networking sites have the potential to succeed in areas where traditional medical approaches have failed. Leone puts it this way: “Social marketing is used to sell products, it certainly should be used to talk about health,” he says. “It takes the locus of control away from the public health system and really makes it about the relationships that exist already between friends.”

Updated CDC Slide Sets

 

Updated Slide Set: Mortality Slide Series
The slides in this series analyze trends in rates and distributions of death in the United States, focusing on deaths due to HIV disease (disease directly or indirectly attributed to HIV, including AIDS). They are based on data compiled by the National Center for Health Statistics from death certificates of US residents in the 50 states and the District of Columbia for the years 1987-2008 (2008 being the latest year for which data are available).

Updated Slide Set: HIV Surveillance by Race/Ethnicity (through 2010)
Slides on HIV infection surveillance by race/ethnicity have been updated with information from the 2010 HIV surveillance report.

Updated Slide Set: HIV Surveillance – Epidemiology of HIV Infection (through 2010)
Slides based on epidemiology of HIV infection have been updated with information from the 2010 HIV surveillance report. 

New Evaluation Toolkit: Patient and Provider Perspectives about Routine HIV Screening in Health Care Settings

New Evaluation Toolkit: Patient and Provider Perspectives about Routine HIV Screening in Health Care Settings


Understanding patient and provider perspectives is an integral component of evaluating clinical programs to improve clinical services. The purpose of this evaluation toolkit is to offer a package of evaluation materials that can be used to determine the effect of expanded HIV screening activities has on patient attitudes about, and their acceptance of, HIV testing.

Download the guide here: [Download not found]

Stimulation Of HIV-Specific Immune Cells Is Necessary To Eliminate Latent HIV

By 

As seen on AIDSBeacon.com

Results from a recent study suggest that stimulation of immune cells that specifically target HIV is necessary to eradicate latent HIV. The results also suggest that simply activating latent HIV is not sufficient to eliminate the virus from the body.

 

Based on the results, the researchers suggested that boosting immune responses through vaccination, followed by reactivation of latent HIV, may be an effective strategy for eradicating HIV.

 

Latent HIV is HIV that is not actively replicating. Since antiretroviral drugs usually work by blocking replication, they do not work on latent HIV. Many researchers believe that activating latent HIV is the key to curing HIV infection; once HIV is activated and begins replicating, scientists hope it will become susceptible to elimination.

 

To date, efforts to cure HIV have focused on reactivating latent HIV virus without activating immune cells. Several drugs have been shown to reactivate latent HIV virus in laboratory studies, including valproic acid (Depakote), Zolinza (vorinostat) (see related AIDS Beacon news), and disulfiram (Antabuse) (see related AIDS Beacon news).

 

According to the study investigators, a critical issue that has not yet been resolved is the fate of infected cells after the virus is reactivated. It is believed that the infected cells die after the virus is reactivated, either as a result of viral replication, or immune system responses, or both.

 

However, the investigators noted that it has not yet been determined whether cells infected with latent HIV are eliminated following reactivation of the virus.

 

In this laboratory-based study, researchers used Zolinza to reactivate latent HIV in CD4 (white blood) cells, then monitored whether the cells died. They also tested the effects on infected CD4 cells of stimulating a type of immune cell called cytolytic T lymphocytes, which are responsible for killing infected cells.

 

The study included 14 HIV-positive adults on highly active antiretroviral therapy (HAART). The investigators treated cells taken from the study participants with Zolinza for six days. They then measured the number of HIV-infected CD4 cells that survived.

 

Results showed that despite successful reactivation of latent HIV, infected CD4 cells were not eliminated. Infected cells were detected in 100 percent of samples treated with Zolinza, in similar amounts to those detected in samples not treated with Zolinza.

 

According to the researchers, this result suggests that reactivation of latent HIV virus alone is not sufficient to eliminate the latent HIV reservoir in CD4 cells.

 

The researchers then examined the ability of participants’ cytolytic T lymphocytes to kill infected CD4 cells.

 

Results showed that only 12 percent of study participants on HAART had cytolytic T lymphocytes that killed CD4 cells infected with latent HIV. The researchers suggested that the weak cytolytic T lymphocyte responses in these patients could be the result of too few HIV-specific cytolytic T lymphocytes or due to reduced function of these cells.

 

However, when researchers stimulated cytolytic T lymphocytes with HIV proteins for six days prior to reactivating latent HIV, the clearance of infected CD4 cells increased significantly.

 

In participants for whom almost no cytolytic T lymphocyte activity was observed without stimulation, the average time to halve the number of CD4 cells infected with latent HIV was reduced from 34 days to less than four days when cytolytic T lymphocytes were stimulated.

 

For more information, please see the study in the journal Immunity

 

 

 

 

 

Chicago Health Center to Pay $715,000 to Settle Claims of Misusing Grants

Howard Brown to pay $715,000 to settle claims of misusing grants

By: Kristen Schorsch April 02, 2012

Article from Chicagobusiness.com

Howard Brown Health Center has agreed to pay $715,000 to several federal agencies to settle allegations that the North Side organization mismanaged grant money.

The agreement resolves an investigation by the inspector general of the U.S. Department of Health and Human Services into the clinic’s handling of more than $3 million between 2005 and 2010.

Howard Brown revealed in April 2010 that it was cooperating with federal authorities on an investigation into the use of federal grant money for a major HIV/AIDS study. Later that year, Howard Brown turned over results of an internal audit showing that grants likely had been used to cover operating expenses during cash shortfalls.

Separately, Howard Brown also plans to repay $1.7 million to Northwestern University, said Jamal Edwards, who assumed the CEO post at Howard Brown after the possible financial mismanagement was detected. Northwestern became the lead agent for the HIV/AIDS study after Howard Brown became the subject of investigation.

The settlement, which covers grants tied to three studies or programs, is a key step in a turnaround of the North Side health clinic network, which was founded in 1974.

“It’s really the first day of the rest of our lives at Howard Brown,” Mr. Edwards said.

The settlement will also place added urgency on fundraising, which Mr. Edwards already has made a priority.

“We certainly do need people to continue to support us,” he said. “Obviously this is going to cause us to redirect a lot of our funds to debt repayment and not services as we would like.”

A pioneer in the treatment of people with HIV and AIDS, Howard Brown is also a research center.

Under the terms of the agreement finalized Friday, Howard Brown is making an immediate payment of $140,000 to the Centers for Disease Control and Prevention and to an agency of Health and Human Services, Mr. Edwards said.

The remaining amount, $575,000, will be paid over three years to the National Institutes of Health, he said.

Details for repaying Northwestern haven’t been finalized, and the repayment likely will take place over the next few years, Mr. Edwards said.

The Office of the Inspector General of Health and Human Services declined to comment.

The federal agencies were seeking $1.1 million, an amount that could have been tripled, Mr. Edwards said.

That Howard Brown turned over its internal audit and cooperated with federal authorities was a key factor in reaching the settlement, he said.

Since becoming chief executive, Mr. Edwards says he has overhauled the clinic’s board and administration and put in place new internal controls and auditing processes.

The organization must still boost revenue, which fell 10 percent, to $16.2 million during the fiscal year ended June 30, from $18.0 million in the prior fiscal year. Mr. Edwards has tried to offset falling revenue by putting renewed emphasis on fundraising and by cutting spending. Expenses were reduced by 26 percent, to $15.0 million in 2011, from $20.2 million in 2010.

CHIPTS on ItunesU!

CHIPTS is now on UCLA ItunesU!

UCLA ItunesU is a free, hosted service for colleges and universities that provides easy access to educational content, including lectures and interviews.  It is a pilot project in conjunction with Apple Inc., which allows them to distribute digital content via the iTunes desktop application.

Organizations and UCLA instructors may upload content— audio, video and PDF files — to the UCLA on iTunes U site. The content can then be downloaded and played on computers or portable devices.

We have already uploaded two lecture podcasts.  Go to ItunesU and check it out!

Men with undetectable HIV in blood still have low levels in their semen

Article from AIDSmap.com

 

 

A study of 101 gay men at the Fenway Health HIV clinic in Boston, USA (Politch) has found that a quarter of men with undetectable viral loads in their blood nonetheless had detectable HIV in their semen.

Although seminal viral load in these men was low (media 200 copies/ml), the researchers suggest that this is still enough to be one of the explanations for ongoing transmission in gay men despite a high proportion being on antiretroviral therapy.

There was a very strong association with detectable HIV in semen and having a current sexually transmitted infection (STI). Six of the eight men whose HIV was undetectable in blood but detectable in semen (so-called virally discordant) had a urethral STI. After adjusting for other factors the researchers concluded that men who had an STI and/or urethritis were 29 times more likely to have viral discordancy.

A quarter of ‘undetectable’ gay men have HIV in semen…

In the Boston study, participants were on average 43 years old and three-quarters were white. They had all been on antiretroviral therapy (ART) for more than three months and 80% for over a year.

Nearly three-quarters were judged as being at high risk of acquiring an STI because they had had unprotected sex in the last three months. Nine of the men were diagnosed with an STI (gonorrhoea, syphilis, chlamydia or non-gonococcal urethritis) and 24 had leukocytospermia or white cells from the immune system in the sperm, indicative of urethral inflammation.

Eighteen of the 101 men had a detectable viral load in their blood; their median blood plasma viral load was 560 copies/ml and ranged from 80 to 640,000 copies/ml. Nine of these 18 men also had detectable HIV in their semen (50%).

Of the 83 men without detectable HIV in their blood, 21 (25%) had detectable HIV in their semen. The median seminal viral load in these men was 200 copies/ml and ranges from 80 to 2560 copies/ml.

As well as having an STI, in multivariate analysis, two other factors remained strongly associated with having detectable HIV in semen in men without it in blood. High levels of the inflammatory cytokine TNF-α were associated with a 14-fold greater risk of a discordant seminal viral load, and having had unprotected insertive anal sex (being ‘top’), which was associated with a more than sevenfold greater risk.

There were therefore in this study low but detectable levels of HIV in the semen of a quarter of men who would register as being ‘virologically suppressed’ on a viral load blood test. To what extent might this be contributing to ongoing HIV transmission in gay men? This is unknown, but the researchers point out that although a viral load below 1000 had rarely been associated with transmission in heterosexual studies, some infections have occurred and animal models suggest that HIV is five times more transmissible via anal than vaginal sex – so a median viral load of 200 would imply a low but definite risk of transmission.

A 2008 study from San Francisco (Butler) found that the median seminal viral load in men transmitting HIV to partners was just 4300 copies/ml and the lowest was 110 copies/ml, while a 2009 study from Brighton in the UK (Fisher) that linked HIV infections in gay men genetically found that two out of 41 transmissions of HIV (5%) were from men with an apparently undetectable viral load.

However studies of the link between viral load and transmission suffer from it being difficult to pin down transmitters in a cohort of gay men with multiple partners and where viral load may be measured months after the transmission (in the Butler study the average gap between transmission and viral load test was 103 days).

One interesting aspect of this study was the higher risk of seminal viral load associated with unprotective insertive sex. The researchers suggest that urethritis in these HIV-positive gay men could be caused by infections with fecal bacteria acquired during sex or even that the virus detected could be passively-carried virus from other HIV-positive gay men. Either way, this would tend to increase the infectiousness of HIV-positive men if they have insertive sex with negative men.

…as do one in 16 ‘low-risk’ heterosexual men

If STIs are implicated in seminal HIV it might be assumed that low-risk men with undetectable blood level of HIV would not have it in their semen. However another study from France (Lambert-Niclot), of HIV-positive heterosexual men in stable relationships who sought sperm-washing, found that 20 out of 304 men (6.6%) had HIV in their semen.

The study was a longitudinal one of 304 heterosexual men who attended a clinic in France seeking sperm-washing for conception between 2001 and 2011. These men between them provided 628 paired blood and semen samples. HIV was detectable in 107 blood samples (17%) and 49 seminal samples (8%). During this time 20 participants (6.6%) provided at least one paired sample where HIV was undetectable in blood (below 40 copies/ml) but detectable in semen. The Seminal viral load ranged from 135 to 2365 copies/ml in these samples.

The proportion of men with a discordant seminal viral load did not vary over time, despite the development of more sophisticated and potent HIV regimens.

Both studies warn that men with undetectable viral load results should not assume they are non-infectious and should be warned that HIV treatment does not appear to reduce the risk of transmitting HIV to zero.

References

Politch JA et al. Highly active antiretroviral therapy does not completely suppress HIV in semen of sexually-active HIV-infected men who have sex with men. AIDS 26:  DOI:10.1097/QAD.0b013e328353b11b. 2012.

Lambert-Niclot S et al. Detection of HIV-1 RNA in seminal plasma samples from treated patients with undetectable HIV-1 RNA in blood plasma in a 2002-2011 survey. AIDS 26: DOI:10.1097/QAD.0b013e328352ae09. 2012.

Butler DM et al. Herpes simplex virus 2 serostatus and viral loads of HIV-1 in blood and semen as risk factors for HIV transmission among men who have sex with men. AIDS 22:1667 – 1671, 2008.

Fisher M et al. Determinants of HIV-1 transmission in men who have sex with men: a combined clinical, epidemiological and phylogenetic approach. AIDS 24(11): 1739–1747. 2010.